Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:574-584
doi: 10.1161/CIRCULATIONAHA.107.735795
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inzucchi, S. E.
Right arrow Articles by McGuire, D. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Inzucchi, S. E.
Right arrow Articles by McGuire, D. K.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Risk Factors
Right arrow Type 2 diabetes
Right arrow Chronic ischemic heart disease

(Circulation. 2008;117:574-584.)
© 2008 American Heart Association, Inc.


New Drugs and Technologies

New Drugs for the Treatment of Diabetes

Part II: Incretin-Based Therapy and Beyond

Silvio E. Inzucchi, MD; Darren K. McGuire, MD, MHSc

From the Section of Endocrinology, Yale University School of Medicine, New Haven, Conn (S.E.I.), and Cardiovascular Division and the Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas (D.K.M.).

Correspondence to Silvio E. Inzucchi, MD, Section of Endocrinology, Yale University School of Medicine, New Haven, CT 06520–8020. E-mail silvio.inzucchi{at}yale.edu

This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs.


Key Words: coronary disease • diabetes mellitus • drugs • heart failure • incretins




This article has been cited by other articles:


Home page
Diabetes CareHome page
C. Bianchi, R. Miccoli, G. Daniele, G. Penno, and S. Del Prato
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
Diabetes Care, November 1, 2009; 32(suppl_2): S342 - S348.
[Full Text] [PDF]


Home page
DiabetesHome page
M. H. Noyan-Ashraf, M. A. Momen, K. Ban, A.-M. Sadi, Y.-Q. Zhou, A. M. Riazi, L. L. Baggio, R. M. Henkelman, M. Husain, and D. J. Drucker
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Diabetes, April 1, 2009; 58(4): 975 - 983.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
D. J. Hausenloy and D. M. Yellon
GLP-1 Therapy: Beyond Glucose Control
Circ Heart Fail, September 1, 2008; 1(3): 147 - 149.
[Full Text] [PDF]